Bristol Myers Squibb pays $475 million for exclusive rights to Dragonfly Therapeutics' IL-12 immunotherapy programme
The Pharma Data
AUGUST 18, 2020
Dragonfly CEO and co-Founder Bill Hanley said of the deal: “We are confident that the talent, experience and commitment to science-driven innovation of the Bristol Myers Squibb team will enable DF6002 to discover novel, lifesaving solutions for patients.”.
Let's personalize your content